Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and admin

Change in fair value of acquisition consideration

Restructuring costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Twist Bioscience Corp

Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. Its products include genes, oligo pools, Next Generation Sequencing (NGS), variant libraries, synthetic controls, antibody discovery, and SARS-CoV-2 Tools. It operates through the following geographical segments: Americas, EMEA, and APAC. The Americas segment consists of the United States of America, Canada, Mexico, and South America. The EMEA segment includes Europe, Middle East, and Africa. The APAC segment consists of Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The company was founded by William Marine Banyai, Emily Marine Leproust, and Bill James Peck on February 4, 2013 and is headquartered in San Francisco, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Twist Bioscience Corp meets Q1 expectations, eyes growth opportunities

Twist Bioscience Corp's Q1 performance met or exceeded expectations across key revenue segments, with a focus on expanding customer base and improving turnaround times.
While facing challenges such as COVID impact on China sales and margin dips due to fixed costs, the company aims for revenue growth and improved margins through strategic execution.
The company's strengths lie in strong gross margins, record bookings in NGS, and efforts towards DNA data storage alliances, positioning for future growth and innovation.
Opportunities include continued customer expansion, Fast Gene market development, and revenue growth driven by NGS and SynBio performance, amidst a value-based pricing strategy.

Twist Bioscience Corp achieves $60.2M revenue in Q2 2023

Twist Bioscience Corp's Q2 2023 earnings call highlighted strong revenue growth, cost reduction efforts, and a focus on achieving profitability. The company is navigating challenges in the biopharma sector while leveraging strengths in technology and sales execution for future growth.

Twist Bioscience Corp reports record Q3 revenue, focuses on growth

Twist Bioscience Corp delivered a strong performance in Q3, with record revenue and strategic product launches driving growth across key segments.
While facing challenges in biopharma revenue and commercial execution, the company is focused on expansion, talent acquisition, and cost management to drive future growth.
With a clear focus on innovation, market expansion, and achieving profitability milestones, Twist Bioscience Corp is well-positioned for future success and market leadership.
The company's strengths in SynBio products, strategic market positioning, and stable funding outlook underscore its potential for sustained growth and value creation.

Twist Bioscience Corp reports robust revenue growth and eyes profitability

Twist Bioscience Corp's Q4 2023 earnings call highlighted strong revenue growth, operational efficiency, and a solid financial position.
The company faces challenges in managing expenses and achieving profitability but sees opportunities in revenue growth and market expansion.
By leveraging strengths in product launches, customer relationships, and revenue growth, Twist Bioscience aims for continued success and margin expansion in fiscal 2024.

Twist Bioscience Corp excels in Q1 2024, focuses on growth

Twist Bioscience Corp's Q1 2024 earnings call highlighted robust revenue growth, margin expansion, and strategic focus on operational efficiency. The company's emphasis on customer needs, premium pricing, and cost efficiency positions it well for future growth and profitability.

Twist Bioscience reports robust Q2 revenue growth and margin targets

Twist Bioscience Corp delivered strong revenue growth and aims for margin improvement, driven by successful product lines and strategic initiatives.
While facing challenges in managing expenses and achieving profitability, the company is well-positioned to leverage market opportunities and regulatory advantages.
With a focus on innovation, market expansion, and margin growth, Twist is poised for continued success and competitive growth in the biopharma sector.
Navigating operational challenges and seizing growth opportunities will be crucial for Twist Bioscience to achieve its financial targets and sustain market leadership.

Twist Bioscience Corp reports robust Q3 revenue growth and profitability outlook

Twist Bioscience Corp delivered strong revenue growth and operational performance in Q3 2024, driven by robust NGS and biopharma revenue streams.
While facing challenges in achieving profitability targets, the company's focus on margin improvement and capacity expansion positions it for future growth.
Guidance for fiscal 2024 indicates promising revenue growth, highlighting opportunities for sustained expansion and enhanced financial performance.

Twist Bioscience Corp reports record revenue and aims for profitability

Twist Bioscience Corp delivered strong financial performance, with record revenue and margin growth driven by key product segments and operational efficiencies.
The company's focus on achieving adjusted EBITDA profitability and cash flow positivity, along with robust fiscal 2025 guidance, signals a path towards sustainable growth.
While challenges like cost management and market competition persist, opportunities in market traction, revenue diversification, and innovation position the company for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. It operates through the following geographical segments: Americas, EMEA, and APAC. The Americas segment consists of the United States of America, Canada, Mexico, and South America. The EMEA segment includes Europe, Middle East, and Africa. The APAC segment focuses on Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The company was founded by William Marine Banyai, Emily Marine Leproust, and Bill James Peck in 2013 and is headquartered in San Francisco, CA.

Twist Bioscience Corporation (NASDAQ:TWST ) Q4 2022 Earnings Conference Call November 18, 2022 8:00 AM ET Company Participants Angela Bitting - Senior Vice President, Corporate Affairs & Chief ESG Officer Emily Leproust - Chief Executive Officer & Co-Founder Jim Thorburn - Chief Financial Officer Conference Call Participants Steven Mah - Cowen Catherine Schulte - RW. Baird Matthew Sykes - Goldman Sachs Luke Sergott - Barclays Vijay Kumar - Evercore ISI Puneet Souda - SVB Securities Rachel Vatnsdal - JPMorgan Chase Madeline Mollman - William Blair Operator Good day, and thank you for standing by.

Twist Bioscience Corporation (TWST) Q4 2022 Earnings Call Transcript

SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the fourth quarter and full year fiscal 2022 ended September 30, 2022.

Twist Bioscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2022 Financial Results

Investors were spooked by a short-seller's allegations.

Why Twist Bioscience Stock Is Crashing This Week

Los Angeles, California--(Newsfile Corp. - November 17, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Twist Bioscience Corporation ("Twist" or "the Company") (NASDAQ: TWST) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces It Is Investigating Claims Against Twist Bioscience Corporation and Encourages Investors with Losses to Contact the Firm

NEW YORK--( BUSINESS WIRE )--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Twist Bioscience Corp (“Twist” or the “Company”) (NASDAQ: TWST) on behalf of Twist stockholders. Our investigation concerns whether Twist has violated the federal securities laws and/or engaged in other unlawful business practices.

TWIST ALERT: Bragar Eagel & Squire, P.C. is Investigating Twist Bioscience Corp on Behalf of Twist Stockholders and Encourages Investors to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / November 16, 2022 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors ofTwist Bioscience Corporation ("Twist" or "the Company") (NASDAQ:TWST) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Twist Bioscience Corporation and Encourages Investors with Losses to Contact the Firm

LOS ANGELES--( BUSINESS WIRE )--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Twist Bioscience Corporation (“Twist” or “the Company”) (NASDAQ: TWST) for violations of the securities laws.

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Twist Bioscience Corporation and Encourages Investors with Losses to Contact the Firm

A negative report by a short-seller drove the biotech's shares downward.

Why Shares of Twist Bioscience Fell 19.92% on Tuesday

SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today addressed a misleading short-seller report issued by Scorpion Capital.

Twist Bioscience Addresses Misleading Short-Seller Report

LOS ANGELES--( BUSINESS WIRE )--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Twist Bioscience Corporation (“Twist” or the “Company”) (NASDAQ: TWST) investors concerning the Company's possible violations of the federal securities laws.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Twist Bioscience Corporation (TWST) on Behalf of Investors

Twist Bioscience Corp.'s stock slid 20% Tuesday, after a blistering short-seller report compared the company to the failed blood-testing startup Theranos, calling it a “cash-burning inferno” and a ” ‘synthetic biology' swindle.”

Twist Bioscience shares slide 20% after short seller compares synthetic DNA provider to Theranos, calling it a ‘cash-burning inferno'

BENSALEM, Pa.--( BUSINESS WIRE )--Law Offices of Howard G. Smith announces an investigation on behalf of Twist Bioscience Corporation (“Twist” or the “Company”) (NASDAQ: TWST) investors concerning the Company's possible violations of federal securities laws.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Twist Bioscience Corporation (TWST) on Behalf of Investors

LOS ANGELES--( BUSINESS WIRE )--The Law Offices of Frank R. Cruz announces an investigation of Twist Bioscience Corporation (“Twist” or the “Company”) (NASDAQ: TWST) on behalf of investors concerning the Company's possible violations of federal securities laws.

The Law Offices of Frank R. Cruz Announces Investigation of Twist Bioscience Corporation (TWST) on Behalf of Investors

Today, we're witnessing an example of how a short report can impact a stock. Reportedly, activist short seller Scorpion Capital just published a report about Twist Bioscience (NASDAQ: TWST ).

Why Is Twist Bioscience (TWST) Stock Down 18% Today?

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Twist Bioscience Corporation and Encourages Investors with Losses to Contact the Firm

New York, New York--(Newsfile Corp. - November 15, 2022) - Wolf Popper LLP is investigating potential securities fraud claims on behalf of purchasers of Twist Bioscience Corporation ("Twist") common stock (NASDAQ: TWST).Twist is a synthetic biology and genomics company that claims to be developing a DNA synthesis platform to industrialize the engineering of biology.

Wolf Popper LLP Announces Investigation on Behalf of Investors in Twist Bioscience Corporation

Shares of Twist Bioscience Corp. TWST, -3.48% plunged 18.7% in premarket trading on Tuesday after Scorpion Capital, an activist short seller, described the company as a "cash-burning inferno" and a "'synthetic biology' swindle." Scorpion alleges that a Twist factory built in Wilsonville, Ore.

Twist Bioscience's stock falls 18% after short seller calls the company a 'cash-burning inferno'

Twist Bioscience (TWST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Twist Bioscience (TWST) Surges 16.1%: Is This an Indication of Further Gains?

Twist Bioscience to Report Fiscal 2022 Fourth Quarter and Full Year Financial Results on Friday, November 18, 2022

The biggest reason why Twist is currently valued at $1.9 billion is the potential to use their silicon DNA synthesis platform for the discovery of new drugs.

Synthetic Biology: Twist Bioscience Revenue Growing From $2 To $200 Million As It Eyes The $186 Billion Antibody Market

Illumina

Twist Bioscience and Illumina Partner to Produce Robust Exome Panel to Advance Research

Twist Bioscience Promotes Patrick Finn, Ph.D., to President and Chief Operating Officer

Twist Bioscience Launches Human Sample ID Kit to Track Whole Blood Samples Through Lab Testing Workflow

Twist Bioscience Earns 2022 Great Place to Work Certification

10X Genomics

Their long-term plans are ambitious, but they haven't performed well as investments recently.

News for Twist Bioscience Corp Stock (TWST)